ProQR Therapeutics N.V. received a Buy rating due to promising phase 1 results for its AX-0810 drug, which showed an 8-fold increase in serum bile acids, surpassing targets and indicating potential to treat biliary atresia. Key upcoming events include full phase 1 data for AX-0810 by end-2026, pediatric data from China in early 2027, and phase 1 results for next-gen AX-0811 by end-2026. With solid cash reserves and a partnership with Eli Lilly, ProQR is positioned for significant value growth through mid-2028.
On August 22, an anonymous Bitcoin user embedded a 255-byte message in block 963,629, announcing a wallet puzzle based on data from Bitcoin's Genesis Block. The puzzle claims to use low-entropy information from the Genesis Block to generate a wallet ...
Boot Barn Holdings is pursuing disciplined expansion with a goal of opening 70 new stores in fiscal year 2027, targeting a long-term total of 1,200 locations. This growth strategy supports sustained double-digit earnings growth, driven by same-store ...
Shiba Inu (SHIB) is facing increased selling pressure as data shows 1.484 billion SHIB tokens moving into exchanges, nearly four times the outflow amount. This surge in inflows suggests investors are preparing to sell, which could lead to a price cor...
ASTER's price dropped sharply from $0.77 to a low of $0.61, a 15% decline, following $4.6 million in long position liquidations triggered by renewed U.S.-Canada trade tensions. This caused panic selling in the derivatives market, with open interest a...
Bitcoin surged over 20% to $79,500, signaling a potential new bull market as analysts note this is a major volatility-adjusted move not seen since 2018. The rally was supported by Ether and Hyperliquid gains, and was influenced by US Treasury's incre...
